Janssen submits sNDAs to FDA for Invega Sustenna to treat schizoaffective disorder
Janssen Pharmaceuticals has submitted supplemental new drug applications (sNDAs) to the US Food and Drug Administration (FDA) seeking approval for its once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to treat s…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Invega | Invega Sustenna | New Drug Applications | Pharmaceuticals